title: Treatment of tobacco dependence: integrating recent progress into practice.
abstract: Tobacco use is one of the leading preventable causes of death in developed countries. Adoption of approaches that have demonstrated efficacy to improve the treatment of tobacco dependence are critical to reduce the health consequences of tobacco use. We summarize the latest epidemiologic data on tobacco use, the mechanisms that underlie tobacco dependence, and advances in pharmacotherapy and nonpharmacologic interventions available for the treatment of tobacco dependence. Specifically, we discuss the use of nicotine replacement therapy, bupropion and varenicline in primary care settings.
authors.affiliation: Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont. bernard_lefoll@camh.net
authors.forename: Bernard
authors.initials: B
authors.lastname: Le Foll
authors.forename: Tony P
authors.initials: TP
authors.lastname: George
mesh_terms: D001521:Behavior Therapy / Q000379:methods; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D015438:Health Behavior; D006291:Health Policy; D006801:Humans; D009538:Nicotine / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011810:Quinoxalines / Q000627:therapeutic use; D020340:Tobacco Use Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline